Clinician Healing Stage 4 Cancers with Vitamins, Antibiotics, and Peptides
41:38 Share

Well, we're going to have a fascinating conversation because we're continuing my series, I call it the Manhattan Project for Cancer, and particularly the metabolic approach to cancer, which looks at cancer as something that is primarily driven by metabolic dysfunction rather than the genetic paradigm, which still continues to rule the establishment framework of looking at cancer research.

And to do so, I'm joined by a guest today. I got to know from my good friend, Dr. Peter McCullough, so shout out to him for introducing us, Dr. John Catanzaro. How are you doing? Hey, David. Nice to meet you. Nice to be on today. Appreciate it so much. Yeah, thanks for taking the time with us to explain what you're doing. This is a subject that's close to my heart. A lot of folks I know

especially when they get to a certain age, get struck by this illness. And there's a lot of folks have continued to say, oh man, you know, if there was a cure for this disease, we'd never know about it because we have such a corrupt system. And so there's a kind of learned helplessness that is baked into this topic. And people are just genuinely afraid of the topic. They don't want to bring it up. They

You know how you have the popular culture that whatever your head thinks about all the time is what happens. So people think if I say that word a lot, it'll make my body get it. So it's got this mystique around it. And I'm trying to demystify it.

uh, the topic and, uh, bring it down to earth and assemble what I would call an Avengers team of the best and brightest, uh, approaches to metabolic treatments for cancer. So that's the context by which I reach out to you now. So thanks for, for giving us your time. Yes. Thank you, Dave. That's great. I like the Avengers thing because when you think about it, you know, you need some superheroes out there, right? I mean, uh, actually this is requires the best of the minds and, uh,

And I think that there's so many brilliant people out there, you know, so many genius type people that are really trying to gather in the, you know, the best of the best. And now with technology advancements today, you know, we have no excuses to, you know, but to use the best of our tools to come up with more precision and personalized type of approaches. Right. And your focus on metabolic aspects of cancer, that's a very important part, right?

of the whole, you know, really the crucible of trying to get into the meat and potatoes of what cancer is all about. Now, you have a PhD. Tell us your background in the topic of cancer and medicine in general. Yeah, you know, I went through integrative oncology training at Bastyr University, so I got my alma mater at Bastyr. It was naturopathic medicine, doctorate in naturopathic medicine.

And then I have a Ph.D. in in theology and ethics, you know, so it's kind of an interesting, very interesting combination. Right. The majority of my work in clinical, clinically integrative oncology, I spent 25 years working with resistant cancers, cancers that had no hope, cancer.

They failed treatments. They, you know, were given maybe six months and less to live. A lot of them were less than that and had opportunity to really challenge and come up with something that's not really, you can't be an inside the box thinker when you're talking about trying to come up with a curative movement in cancer, right? You really have to be, have an engineering mindset and

And it's really a counterintuitive process when you work with it. So I've had opportunity of seeing so many different cases for my clinical years, 25 years of clinical practice and started Neo7 Bioscience with a good colleague and friend who's a Johns Hopkins molecular biophysicist. And we started Neo7 Bioscience in 2019 to continue the work, right? Because we were having such great experience working

with good outcomes with patients who came to us with a no hope scenario and they wind up living you know we have some patients living that are 14 plus years after we treated them years ago you know so that's fantastic so you know you you have a passion for this topic uh what drew you into what was there an inciting incident a personal thing or what was the thing that got you to start this company

Yeah, that's a great way to start. Because I think that, you know, when it comes to the family part of it, because one of my daughters actually was experiencing a continued bout of pneumonia that was actually, we kept on going to the emergency room and she was getting worse. She winds up having this condition called status asthmaticus and

And, you know, they were loading her with steroids. She was getting sicker. Her immune system was getting, you know, really suppressed. Right. So I just thought, you know, there's got to be something better than this. And so I researched it out and and sure enough, come, you know, took the natural medicine route where that's when I became acquainted with Bastyr U.

And my daughter, within a period of three weeks, got better after going on a protocol, natural medicine protocol. And I was just totally impressed. And I said, that's the kind of medicine I want to practice. Right. Now, before that, I was in the aviation aerospace industry. So I was in high technology in the Air Force and also at the Boeing company. So I actually had, you know, a lot of technology experience.

thrown at me at an early age. And so it came useful when I went through best year of medical school and I graduated, I was able to take, you know, the, the, the, the technology and the best of what I've learned in clinical medicine and put them together. And that's how Neo7 Bioscience started, you know? Yeah. So tell us about the name Neo7. What does that mean?

Well, you know, NEO 7 is just kind of like taking a renewed approach and kind of like doing something that's out of, you know, out of the norm, right? I usually like to say a counterintuitive approach, which means that everybody wants to go and take a rational approach. Well, we take an approach that's kind of like, you know, a counterintuitive type engineering approach in, you know, putting the nuts and bolts together and making it a utility, making it useful for the person.

And so that's what we were able to do. And so we thought Neo means, you know, new and seven is an infinite number and a really good number.

lucky number. And then we were also thinking, and we would take it around the world to the seven continents. Right. So we were just like, wow, this is a real powerful, very powerful business approach to where we can actually, you know, we have a large vision and a large mission. And we're just, you know, we've said, let's move this forward because I know how many patients I helped when I was in clinical practice. Cause we had, you know, five, six other physicians working at our center besides me.

And we influenced a lot of, you know, had a large influence on a lot of people's health for the better, good favorable outcomes. And I just thought, you know what, it would be great to start a company that would be able to have even a larger sphere of impact to a broader amount of people, you know, larger population. So, you know, I've looked at this topic from various different perspectives over the years.

And, you know, there's a lot of them. I won't go through all the ones that I've explored, but a lot of different competing alternative approaches to cancer that all of them, of course, most of them are vilified or ignored by the establishment. Yeah. And that's OK. But we have to kind of stay focused on trying to figure out what is the common thread between all of them.

So, for example, I remember there was this Italian guy. I don't know if – I can't remember his name. I should have looked it up before we started. In Italy, who was using baking soda to treat tumors. Uh-huh. Familiar with that work, yes. And was it his name so it would give him justice? I can't remember his name either for some reason. He would just go right in there and target the tumors with baking soda. He'd said it was like a fungus-like material. Yeah, yes. He was really keen on that. Uh-huh.

Um, and so, you know, I thought about that and I, then I looked at, you know, things like, um, Dr. Ray Pete, the late biologist who was frequently on my show. Um, he, he told me a lot about the CO2 of, you know, how CO2 is kind of works when your body is able to, um, retain and use CO2. It's not just a waste product as we're told in the academic textbooks.

Right, right. CO2 kind of works to help you in a variety of different ways, but just in a broad sense, it seems to be kind of like if your body is very taller of CO2, it's going to be less likely to build up excess lactic acid, which is the

kind of the environment by which cancer thrives, right? So I thought about, you know, he said the high altitude areas is where your body starts to be more efficient at utilizing and tolerating CO2 and how those have the lowest rates of cancer mortality.

So I put baking soda together from the Italian guy. I look at CO2 in relationship to altitude and its efficient use in the body when you're at higher altitude. Yeah, I think the guy's name is Simoncini. Okay. Yeah, it's Tullio Simoncini over in Italy. Yeah. You have all these different, you know, and then you have my friend, Dr. Thomas Seyfried. I've been interviewing him since like 2016 or so, 2017. And he's been at it for a long time in Boston College.

using the ketogenic therapy and he targets glucose and glutamine and has this press pulse method of of doing this and he's had some pretty remarkable successes against some very aggressive cancers and then you have you know there's there's the the approach that i've learned about from dr michael asante and i he's over in southford university now he's here in um

North America, again, he's the head of a new company that he started in Ottawa. But as an American, he was researching for a long time doxycycline, which is this tetracycline antibiotic that was very widely used all over the world. And having some success with that and Z-Pak for cancer stem cells, metastatic cancer stem cells. Yeah. Right?

That's perfect because the cancer, anti-cancer stemness, like you're saying, it was doxycycline, zithromycin, and vitamin C. It's a triad. It's a perfect triad for dropping down cancer stemness, and it works. Wow. Yeah. So how do you, you know, so it seems like there's, again, I like to look at, like,

This is why I call it the Manhattan Project for Cancer, and I'm not going to do it justice, but just doing a show version of it, podcast format version of it. You're trying to put everything on the wall, like when you have a murder mystery. You want to connect the dots. Okay, we were found here, there, there. You're looking at all these variables, and you're trying to find out what's the common image here? What's the pattern here that we can make this kind of strike to take out this disease?

So I guess the first place to start is why do we get cancer and why do we have it at the rates that we have now in the last century? Yeah, you know, the thing that the word that they use is the exposome, which is everything is on the outside. That's the outside elements, the environment, various type of things, intrinsic issues in the body, the body's ability not to maybe adapt to certain changes that are occurring faster than the body's ability to adapt to them.

of these different factors come into play. And then if you put in the mix, the intrinsic, uh, uh,

susceptibility that people have, you know, that also comes into the mix. You know, people are struggling with chronic infections, chronic inflammation, autoimmune disease. They're struggling with maybe polypharmacy, which means that they've been given so many different drugs over the years, their body, their systems are just like hit sideways by it. You know, all of these different things facilitate, you know, this type of process. I mean, you know, even as recent as the mRNA vaccine,

vaccine complications you can see that the spike protein you know has has hit so many different people sideways and creating you know unstable molecular signaling in the body that's what we specialize in we're specializing in and looking at you know what influences the molecular patterns of the person's total system interface and and staying healthy you know what i mean

And it's a multifactorial type of thing. It's never about just this one thing about cancer.

And also it's a multi, it's a multifactorial signaling issue. So I know as you think about a multifactorial thing that things that hit the body, like we were just saying, but it's also a multifactorial signaling thing. So like, you know, how do we treat cancer? Well, we can't just single one thing out and call it good because the, the body, the cancer always develops this resistance, right?

You know, it's like the resistance against an agent that was really good that came in and all of a sudden it's not working anymore because the cancer is like notorious for creating, you know, these different type of what we call exponential shifts and mutations. And you got to stay ahead of those patterns. So that's why I say it's never about one signal focus and it's never about one thing to come up with the curative movement for cancer, you know.

So how would you describe why do we get it? Is it, you know, people have different analogies or kind of narratives for why humans developed this? Do you think you said environmental factors? Is it?

Is it excess sugar, processed flour, seed oils, blue light exposure? Yeah. Everything that Bobby talks about, Bobby Kennedy, right? I mean, everything you're talking about as far as these additives, these food, the preservatives, the lack of, you know, these GMO issues, any kind of manipulation, genetic manipulation of our food, you know, the, the, the,

various type of drugs that are coming in that are being used for everything. I mean, people just incompatible with their bodies, the environmental shifts, heavy metals, you know, disturbance of our microbiome. So the microflora mismanagement, I mean, there's a lot of stuff that's going on there. That's really huge.

in the microbiome management of things, right? Because our bodies are trying to constantly protect against these, you know, to resist them. The body is really good at, I usually say the body's really good at forward and reverse engineering. It has a natural posture to want to do that. But when you start bringing so many different things in, assaulting the systems, then, you know, it's hard for the body to keep up. So it starts to downregulate and shift and suppress. And

And that's what we don't want. So that's why, you know, go, you know, approaching this from a very intelligent process is important, you know, minimize the amount of exposures, all clean eating, you know, good forms of exercise, fresh air, sun, et cetera, you know, pure water, all of these different things are so important to kind of nurture the body and then making sure that you're looking at the, you know, the core root,

integrity of the body overall, right? So like how does the body, you know, what kind of adaptations does the body need to go through to be able to get stronger and resist these challenges? Yeah. Right? Yeah. It's popular within the alternative health world to say sugar is driving cancer, excess sugar consumption.

And yeah, you have folks like Dr. Ray P and others that follow his kind of thinking that say, no, it's the inability to effectively use sugar, primarily driven by excess, you know, omega-6 fatty acids in the blood that cause the dysregulation, the mitochondrial dysfunction, etc.

And so it's because of the fact that most people are metabolically broken and then they have a high-fat, high-sugar diet on top of that, which is the environment for cancer on a basic, broad, macro scale.

Do you agree with either one of those perspectives?

And then when you have this flux of all kinds of additives and sugars coming in that your body doesn't metabolize them appropriately, it's only going to feed that inflammatory environment. So chronic inflammatory activity in the body really raises up the risk for creating mutations that are unfavorable in the body that feed the cancer activity, right? Yes. I mean, and everybody knows about the Warburg effect and

And the metabolism and how these cells are supposed to metabolize and how cancer cells metabolize differently. Differences in pH, right? The pH environment is a big deal. You know, when you're when you're moving in a pH flux and you're favoring pH, that's not, you know, not good for healthy cells, but really feeds the cancer cells. You know, these are things that are really important to look at.

So, you know, Georgie Dinkov is a guest we've had on recently. He talked about his work with B vitamins, B1, B3, B7. And he used aspirin with these very lethal, aggressive, fast-growing tumor in the lab on rodents. And he found really remarkable results with just that simple combination. And he wanted to use the simplest combination possible.

And, you know, in non-lethal doses as it would be equivalent to human weights and so forth. And he was surprised that there was total elimination of the tumor and the rodents lived a full life, it seemed like. So,

Just one little study can't change the whole world, but there needs to be more research on this. But I believe you use B vitamin therapy, right, for your research? Yes, I use a triple B vitamin therapy.

You know, the triple B vitamin along with the vitamin C artesonate in a lot of patients very successfully, along with that anti-cancer stem, this that you were talking about, the triple azithromycin, doxycycline, and the vitamin C artesonate, very powerful. So you put the triple Bs in there.

And, you know, and they really made a big impact on the treatment along with personalized peptides, as I was mentioning to you before we got on. But yes, very powerful, very powerful way of going about treating cancer. How do the B vitamins affect cancer? You know, you said you've just explained that for the audience. What is your mechanism of action that you see taking place that the

doxycycline, Z-Pak, and vitamin C, do you lump them in one group as the way they target the problem and then the B vitamins in a different approach or what's going on in your mind? Yeah, very good. You know, the thing is, is that we look at it from the standpoint of the triple therapy using the azithromycin, doxycycline, and vitamin C relationship. And that really facilitates an apoptosis, which means it accelerates cancer cell death.

Right. Because the cancer stem this cannot consistently they can't reproduce themselves because of the actions of those three in combination.

And then you've got your triple B's are actually really pushing the immune relationship. So in other words, it's getting immune regulation in there, stimulating the defense mechanisms of your T cells, natural killer cells and those things. So it kind of goes hand in hand where you get that recruitment of your anti-cancer defense and you get the accelerated dying effect of those cancer cells.

Wow. Now, what about vitamin D? A lot of folks say you can't, you know, if you're deficient in vitamin D, that's the foundation for cancer. And if you're not, if you've got good amounts of vitamin D, that's not a good environment for cancer to succeed. Yeah, that's true. Because, you know, I take about 25,000 units a day of D, right?

I mean, you're supposed to get you 25,000. I use it. Don't they recommend like 5,000 usually? So that's really, that's really low for what people. Yeah. Yeah. That's kind of, that's kind of like a maintenance dose on 5,000. You know, they don't like to say to go any past 5,000 because they don't read, you know, they have to stay within their certain recommendations. But I say, you know, I need more D and if you're not going to get enough from it, you know, from the sun, you know,

You know, I mean, you got to have it some other way. So vitamin D is a very important player in immune regulation. Absolutely. So tell us a little bit about your approach and what stands out uniquely about the NEO7 bioscience approach.

Well, Neo7 Bioscience approach, you know, we're talking about all these wonderful integrations, like you're saying, I mean, which from a metabolic standpoint, very important. And Neo7 Bioscience takes, it's a hub strategy. So in other words, we get all of the molecular data from the patient, from the blood, urine, tumor tissue, et cetera. Everything that we get from that samples, we build the high, what we call high definition molecular data set.

which looks at every gene protein in a relationship in the body that controls, you know, 37 plus trillion cell activity in the body, right? Yeah, but we have 37.9 trillion cells and more controlling, you know, some 3000 different proteins. And when we talk about 3 billion base pairs of DNA transcribing, you know, when we talk about all this molecular stuff that's happening,

you got to know what's happening with the signal interface because protein to protein interactions and protein to protein communication happens every second of the day in our bodies. And so whenever we have a signal interface that has gone sideways, you don't know that these are usually hidden molecular drivers. So what Neo7 Bioscience does is we find those hidden molecular faults

And we develop a personalized peptide engineering against those faulty targets, specifically matched to the patient. And in cancer, we have such a, you know, a high success rate because we're N of one, which means that we're not disease focused. We're not N of one of the disease. We're N of one of the person.

So whatever the person is, you know, if they're diagnosed with a serious cancer, we get to see the underlying signal interface so that we can target it appropriately. That, you know, we hit their expression because you can have two people with the same cancers. Right. But have a totally different target in a target identity.

So in other words, you can have maybe similar targets, but their personalized engineering to those targets are totally different. So that means that there's different molecular switches that fight cancer differently in each person. And no person is the same. So we actually do the surveillance to get that identity. And then we develop the personalized engineering to hit those bad signals and correct them. So you use peptides. What are peptides?

Yeah, peptides are basically the building blocks of proteins, right? They're amino acids. They're a group of amino acids that build a certain protein.

And then, like I said, there's so many different proteins in the body that keep normal function, right? So you want to be able to extend the integrity of those proteins and you want to be able to be sure that they're, you know, functionally strong. And that's what we're identifying. So when we design a personalized peptide engineering specifically to those targets, we're not taking an off-the-shelf product to do that. We're taking something from scratch and engineering it directly related to that person's

molecular expression. So in other words, it's an assembly of amino acids that build a certain interface to address the faulty signal, right? From the very beginning. Is this using like CRISPR editing or how does it do this personalized approach? Well, CRISPR is more on the gene focus, right? So we understand CRISPR. Neo7 Bioscience is understanding CRISPR quite well. And

But really what we're using is we're just using basic peptide engineering. So which means that we are taking the protein model and we take what we know is specific to the patient and we build it in a scaffold system to address that protein path. So rather than trying to splice something in or out, like in other words, X this out and place this in, which is CRISPR.

You know, we're letting the body have a natural rhythmic mimicry itself. So it does that editing in the body. So it's an in-body editing system rather than a CRISPR shifting, you know, or manipulation. So would your therapy be in the same basket of metabolic therapies or would this be more? Oh, yeah. Yeah.

Yeah, this would be this would be molecular, a very strong influence in metabolic because, you know, some of those protein to protein communication paths affect the mitochondria, how the mitochondria output is, you know, whether or not it's generating enough ATPs to keep energy of the cell going.

Whether or not it's cross-talking with the endoplasmic reticulum, which, you know, is responsible for making, you know, and getting those proteins to package out, right? So when you really think about it, you know, we're talking about influences as a hub strategy to influence the cellular machinery, the internal structures, mitochondria, endoplasmic reticulum, Golgi, the extracellular space, the nucleus as well. I mean, we're addressing all of those things.

And so what does that, what does it look like in the form of therapy? What is it? What is it? Is it something you take orally? Well, it's a personalized drug. Yeah. It's a personalized drug that's developed, you know, from end to end, from time you sample, submit a sample to the manufacturing of the personalized peptide through the manufacturer. It has to go through the pharmacy. The physicians have to prescribe it. So our, which are participating physician, Neo7 physicians or clinics are

And it takes a total of 10 or 11 weeks from end to end sample submission to the delivery of the personalized drug. It's a lyophilized powder that has all of the signal targets in there. And it's given by injection, either intranormal, subcutaneous, IM, intratumoral, TMS.

intravenously. Some people have nebulized it, like our patients that are neurodegenerative patients like Parkinson's and Alzheimer's and some of these ALS, they'll nebulize it, you know, so all routes of administration. And it's usually for like cancer, it's a 12 month therapy. So it takes, you know, they have enough of their personalized drug for 12 months and they are usually injecting themselves about three times a week.

On average, you know, with these very serious cancers, because you got to pull them out of that tailspin, you know what I mean? So on the front side, you have to be a little more aggressive. It usually takes about 12 to 18 months to get them into a real positive rate of change so that their cancer, their tumors are shrinking, better quality of life. And a lot of times we achieve that no evidence of disease, like within 18 months, right?

Right. So and again, the reason for that, it's N of one N to the person engineering. It's specific to the person. But you can. So you do use the B vitamins and antibiotics as well. Yes. Yes. We use all those combinations. We use all those combinations, you know, like in GBM antibiotics.

glioblastomas for instance we even use like tumor treating fields like the i don't know if you ever heard of the optune the optune system where they put the helmet on and they got these electric fields well i'll tell you the peptides they're polar molecules

They like to, you know, they get into spaces. You talk about the biophysics of it, right? I mean, they're just live molecules. So they're going to get to their space. And then you put the tumor treating fields like the Optune GeoHelmet for resistant brain tumors. Nice combination. Put these other things in like triple Bs and the, you know, doxycycline, azithromycin, the vitamin C together are

a lot of these other things in there, a lot of strategies. So what we do is we have the, we produce the hub strategy and then we make recommendations for any type of integrative triage that would accent the body's ability to do, have a higher defense posture and regulate against the cancer. Another one they've mentioned a lot is ivermectin and this other, what's that one? Yeah.

Yeah, you know, mebendazole and fenbendazole and ivermectin, a lot of the time- They work totally different ways than the vitamins and the antibiotics? Yeah, they're a different mechanism of action. They do have what they call anti-proliferative effects.

anti-proliferation you know they work on different pathways of the cascade so they have a different action and uh and and cancer resistance to pretty effect like fenbendazole levendazole these are all you know they've been seen seemingly to really facilitate a a real uh direct action against metastatic activity right uh pretty pretty impressive do you also uh

Do you do anything with therapeutic ketosis or do you don't really do dietary recommendations? Well, we do make recommendations. We like to say that the combination of more of the ketone effects and focus along with things like the paleo diet, you know, combination paleo and keto diet,

work nicely if you kind of if you stagger them right or or if you kind of like it's kind of like remember i said it's never about one thing you know some people want to go strictly vegetarian and and for some people that's not necessarily productive uh but if you if you take the best of the best like of paleo keto and vegetarianism you can come up with a nice kind of blend uh to cyclically address the body's ability to get to a higher state of defense and

So if you stay on one dietary regimen, you know, the body gets used to that. And again, it's like with anything, it's the same old, same old for the body. So you want to be able to keto to change the metabolism, paleo to support the system for immune, better immune resilience. And then, you know, vegetarianism is to put you more into a detox mode.

type of movement to where your body is cleansing itself because it's, you know, talk about strict vegetarianism. It's usually a very high pure food focus generally, but not everybody could do strict vegetarianism. As you know, some people have problems with blood anemias and things like that, that they can't maintain just by strict vegetarianism. So do you believe that there's basically more than one way to,

to ascend the mountain of cancer treatment. It's not just, and it's not, there's not just one formula or so forth. It's always going to be unique. Yeah, it's going to be unique and it's always going to be, it's never about the one thing. It's always about a multifactorial type of approach to a multifactorial problem. It's never about one target. It's about many. It's like in the conventional medicine, they always talk about

focusing on one target like Keytruda or Opdivo, which are, you know, your checkpoint inhibitors. Like, let's go for the gusto there, burn out those checkpoints. And after a while, people don't respond to those things because they become resistant to it. You know, so it's the thing is, is you have to keep in mind that it's a multifactorial, multi-targeted,

uh, type of, uh, uh, problem. And then you have to approach it that way. So get the best of the best triage, the best, you know, cycle them in and out. Like in other words, cycle your therapies in and out, use the best of the repurposed drugs for anti-cancer approaches, uh, very important, and then have a really great hub strategy.

And that's what Neo7 Bioscience does. We want to produce the hub strategy to direct the signal interface to really push and enhance your ability to regenerate and recover and get that disease totally eradicated. So is the idea to restore the cancerous cells to normal behavior and function, or is it to kill them?

Just kill them off. Eradicate them. Get them out of there. Lice them up. Do the apoptosis deal. Licing is what you'll see. Is that one of the side effects that will let you know that it's working when you take your cancer? Yeah, you get the lysis of the cancer cells and you get the breakdown of the tumor microenvironment. They say that looks like egg white. What?

Like in the bathroom or something? Yeah, it's a disgusting thing that comes out of your body. Yeah. But that's how you know that your method is working there? Yeah. And then you also notice, you know, well, people notice that they get, you know, dramatically better, more energy, et cetera, et cetera. And they notice their body changing, their tumors shrinking, all of those things, you know.

So if folks are interested in learning more about your method and your approach, where can they go? Well, they go to our website at neosemibioscience.com, you know, and you go on there and you'll see on the website, you go to inquiries and you can inquire about,

That's a good way of doing it. I'm on X. So I'm Dr. John C. Beyond Bio on X. And then I'm also on Substack, Decision Junction on Substack. You know, those are good ways to go about it. But mainly the website, neos7bioscience.com. Yeah.

You've dealt with folks with stage four, right? Pretty bad cases. Is that where you mostly get people at that stage? Yeah, very bad. Usually very extreme, you know, stage four aggressive cancers. That's what we wind up seeing a lot of.

Yeah. And what are your, what's your success rate? Do you have any numbers or statistics? Yeah. Our outcomes are, you know, pushing 75% with very aggressive cancers that have no hope. So we're looking, you know, 75% means tumor reduction, better quality of life and extended quality of life. Right. So we have, and we've been, you know, treating a lot of people with a lot of resistant diseases. I mean, like we had one, uh,

A recent patient that had a PSA level of 4,000, right? Jameer, a PSA level of 4,000. Tell folks what that means, where they're not familiar with that. It's a prostate-specific antigen that is indicating that the cancer activity of the prostate is really high.

So PSA of 4000 and then tumor in the neck tumor in the groin large tumor in the abdomen gained a lot of fluid because of the metastases. You know, he didn't want to do conventional therapy. He said, I'm doing all integrative therapy, but he wasn't getting anywhere. So when he came to us and we got him on, you know, got his design made up and then started him within eight weeks.

Tumors in the abdomen, neck and groin all reduced in size. He doesn't have any tumors anymore. And his PSA level went down to 14 from 4000. Right. So that means that the very aggressive battle cry went out.

in the body to go after those bad cells and they lice them all up and he lost 41 pounds of metastatic fluid. He gained that much fluid because of the metastases and he lost it all. So the guy is now out of a

the wheelchair and up and around walking. And, you know, he's close to 80 years old. Wow. So age is not a deterrent to regenerative resilience. It isn't. You just have to have the right ingredients. You know what I mean? That's fantastic. Well, do you have other diseases that you guys, I think you mentioned that you deal with as well?

Yeah, autoimmune disease, neurodegenerative disease. We have an ALS case that recently we designed for. This guy wasn't able to breathe very well. He couldn't swallow and he wasn't able to move his body. You know, progressive activity with ALS, as you're aware, is a pretty serious disease.

And within a period of eight weeks, this guy, his diaphragm started working again. He's able to swallow and he's moving a lot better. And for the first time, he's traveling down to Africa, right? So you can tell he's feeling good because he's traveling around. And this is the doctor that he's working with. That's the doctor that's a NEO7 participating doctor. That's her report to us about how he's doing, right? So yeah.

And then he's doing other things too, along with the hub strategy at Neo7. So he's doing things like tissue plasmapheresis and he's doing, you know, he's doing a lot of nutritive therapies and some great stuff, you know, together. And the guy's really making a lot of progress. And that's very encouraging for ALS, you know. What's success look like to you in the next five years, say, you know?

We can only get better at what we do, right? Remember when I was saying earlier that with our increasing technology, we have an augmented hybrid intelligence model, which means that human intelligence is the core. But now when we talk about human intelligence, it's about taking all the best and the brightest minds of human intelligence and incorporating them together. We have a great team at Neo7 Bioscience. And then using the best of deep understanding

deep learning and molecular modeling, right? So in other words, our hybrid intelligence is not unsupervised intelligence. It's intelligence with that purpose of creating a product that is going to be useful and have utility, which means that it's going to do something good for somebody

and and grow and get better you know so as we get more data we learn the system learns and before you know it you got more witty inventions that come out from that from that you know what i mean

Well, very good. I'm looking forward to seeing what you guys have to report in the future. So we'll stay in touch and keep us updated on how things are going. Any success stories or breakthroughs that you'd like to share with your research is always welcome. Absolutely, David. Thank you. Thank you for having me on. It was really exciting. And I was excited for today. And I'm so glad that we met. I'm so glad that we met together. Thank you. I appreciate it. So check out Neo7 Bioscience. Again, the website one more time, sir.

Neo7Bioscience.com. All right. Thank you. You betcha.